MP33-07 ANTI-PROGRAMMED DEATH RECEPTOR 1 PLUS ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODIES AND COMBINATION CHEMOTHERAPY FOR RELAPSED LOCALLY ADVANCED AND/OR METASTATIC PENILE SQUAMOUS CELL CARCINOMA

Abstract

You have accessJournal of UrologyCME1 Apr 2023MP33-07 ANTI-PROGRAMMED DEATH RECEPTOR 1 PLUS ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODIES AND COMBINATION CHEMOTHERAPY FOR RELAPSED LOCALLY ADVANCED AND/OR METASTATIC PENILE SQUAMOUS CELL CARCINOMA Longbin Xiong, Lichao Wei, Ting Xue, Ru Yan, Tingyu Liu, Lijuan Jiang, Huali Ma, Yanxia Shi, Xin An, Yijun Zhang, Shengjie Guo, Kai Yao, Fangjian Zhou, and Hui Han Longbin XiongLongbin Xiong More articles by this author , Lichao WeiLichao Wei More articles by this author , Ting XueTing Xue More articles by this author , Ru YanRu Yan More articles by this author , Tingyu LiuTingyu Liu More articles by this author , Lijuan JiangLijuan Jiang More articles by this author , Huali MaHuali Ma More articles by this author , Yanxia ShiYanxia Shi More articles by this author , Xin AnXin An More articles by this author , Yijun ZhangYijun Zhang More articles by this author , Shengjie GuoShengjie Guo More articles by this author , Kai YaoKai Yao More articles by this author , Fangjian ZhouFangjian Zhou More articles by this author , and Hui HanHui Han More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003266.07AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Relapsed locally advanced and/or metastatic penile cancer has an extremely poor prognosis with a need for effective therapy. This study retrospectively estimated the efficacy and tolerability of anti-programmed death receptor-1 (PD1) plus anti-epidermal growth factor receptor (EGFR) antibodies and combination chemotherapy in relapsed locally advanced and/or metastatic penile squamous cell carcinoma. METHODS: A retrospective review of 30 relapsed locally advanced and/or metastatic (T4/N2-3/M1) penile squamous cell carcinoma received anti-PD1 plus anti-EGFR antibodies and cisplatin-based chemotherapy in Sun Yat-sen University Cancer Center from Jan 2018 to Aug 2022. Of 15 were chemotherapy-pretreated patients, and the remaining 15 were chemotherapy-naïve patients. Clinical responses were assessed using the Response Evaluation Criteria in Solid Tumours (RECIST v1.1) in 27 evaluable patients. Adverse events (AEs) were graded according to Common Terminology Criteria for Adverse Events (CTCAE v5.0). Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method. RESULTS: Partial responses were observed in 63% (17/27) patients, and 14 were chemotherapy-naïve patients. The objective response rate (ORR) was 100% (14/14) and 23% (3/13) in chemotherapy-naïve and chemotherapy-pretreated patients, respectively. Fourteen patients subsequently received consolidated surgery. Eight patients achieved pathological complete response, and six were chemotherapy-naïve patients. The median follow-up time was 11.4 (range: 2.3-36.2) months. The median PFS and OS were 15.6 (1.0-32.6) and 20.9 (10.5-30.3) months in chemotherapy-pretreated patients, respectively. However, these were not reached in overall cohort and chemotherapy-naïve patients. 2-year PFS (OS) was 53% (62%) in overall cohort, whereas 75% (79%) and 35% (47%) in chemotherapy-naïve and chemotherapy-pretreated patients, respectively. Treatment-related AEs were experienced by all patients, with 60% (18/30) experiencing a grade 3 or 4 AEs. The most common grade 3-4 treatment-related AEs were lymphopenia (40%), anemia (23%), and neutropenia (13%). CONCLUSIONS: Anti-PD1 antibody plus anti-EGFR antibody and cisplatin-based combination chemotherapy were effective, well-tolerated, and satisfying long-term survival outcome for relapsed locally advanced and/or metastatic penile squamous cell carcinoma. However, prolonged follow-up and large prospective clinical trials are needed to validate the findings on this important issue. Source of Funding: This study was supported by the National Natural Science Foundation of China (No. 81772755). © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e452 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Longbin Xiong More articles by this author Lichao Wei More articles by this author Ting Xue More articles by this author Ru Yan More articles by this author Tingyu Liu More articles by this author Lijuan Jiang More articles by this author Huali Ma More articles by this author Yanxia Shi More articles by this author Xin An More articles by this author Yijun Zhang More articles by this author Shengjie Guo More articles by this author Kai Yao More articles by this author Fangjian Zhou More articles by this author Hui Han More articles by this author Expand All Advertisement PDF downloadLoading ...